Details for Patent: 9,198,882
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,198,882 protect, and when does it expire?
Patent 9,198,882 protects PROCYSBI and is included in two NDAs.
Protection for PROCYSBI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-seven patent family members in eighteen countries.
Summary for Patent: 9,198,882
Title: | Enterically coated cysteamine, cystamine and derivatives thereof |
Abstract: | The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects. |
Inventor(s): | Dohil; Ranjan (San Diego, CA), Schneider; Jerry (La Jolla, CA) |
Assignee: | The Regents of the University of California (Oakland, CA) |
Application Number: | 14/752,383 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,198,882 |
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 9,198,882
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Horizon | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-001 | Apr 30, 2013 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Horizon | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-002 | Apr 30, 2013 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Horizon | PROCYSBI | cysteamine bitartrate | GRANULE, DELAYED RELEASE;ORAL | 213491-001 | Feb 14, 2020 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Horizon | PROCYSBI | cysteamine bitartrate | GRANULE, DELAYED RELEASE;ORAL | 213491-002 | Feb 14, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,198,882
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2007210005 | See Plans and Pricing | |||
Brazil | PI0707277 | See Plans and Pricing | |||
Canada | 2640531 | See Plans and Pricing | |||
Cyprus | 1113690 | See Plans and Pricing | |||
Denmark | 1919458 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |